# Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002)

> **NCT06242691** · PHASE1,PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 13 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **BIOLOGICAL:** MK-1200
- **DRUG:** Antiemetic

## Key facts

- **NCT ID:** NCT06242691
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-28
- **Primary completion:** 2025-06-17
- **Final completion:** 2025-06-17
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06242691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06242691, "Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06242691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*